Table XXI.

Operative procedure	Reference *Abstracts corresponding to references can be found using the listing "RCTs by alphabetical order" or "RCTs by topic."*	Summary
Various Sclerosing agent, dose and concentration	Hamel-Desnos C, Allaert FA, Benigni J-P, Boitelle G, Chleir F, Ouvry P,et al. [Etude 3/1. Mousse de polidocanol 3% *versus* 1% dans la grande veine saphène: premiers résultats.] *Phlébologie*. 2005;58:165-73. In French.	158 patients with incompetent GSV of mean diameter 6.1 mm UGFS with Turbofoam® Two concentrations of polidocanol Group I (N=79): polidocanol 1%; V= 3.1ml Group II (N=79): polidocanol 3%; V= 3.1ml **Results at 3 weeks of follow-up:** *Reflux abolition (RA):* 91.1% in group I *vs* 91.1% in group II **Results at 6 months of follow-up:** 14 patients lost to follow-up *Reflux abolition (RA):*80% in group I and group II
	Rao J, Wildemore JK, Goldman MP. Double-Blind Prospective Comparative Trial between Foamed and Liquid Polidocanol and Sodium Tetradecyl Sulfate in the Treatment of Varicose and Telangiectatic Leg Veins.*Dermatol Surg*. 2005;36:631-5	Twenty subjects with telangiectatic of varicose leg veins without incompetence at SFJ or SPJ were randomized and treated either by polidocanol or sodium tetradecyl sulfate at various dose **Results at 12 weeks** Assessed by digital photographs and questionnaire. Subjects were satisfied with treatment in 83%, regardless of the sclerosing agent used or the vein size treated. There was no statistically significant difference in adverse effects between each group.
	Ceulen RPM, Bullens-Goessens YIJM, Pi-Van De Venne SJA, Nelemans PJ, Veraart JCJM, Sommer A. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% *versus* 3% polidocanol foam: results of a randomized controlled trial with1-Year follow-up. *Dermatol Surg.* 2007;33:276-8	80 patients with incompetent GSV (including SFJ) of mean diameter 5.4 mm. UGFS single injection with catheter Group I (N=40): polidocanol 1%; V= 4.6 ml Group II (N=40): polidocanol 3%; V= 4.4 ml **Results at 1 week of follow-up:** *Reflux abolition (RA):* 86.7% in group I *vs* 91.5% in group II (P=NS) **Results at 1 year of follow-up:** *Reflux abolition (RA):* 69.5% in group I *vs* 80.1% in group II (P=NS) *Cosmetic improvement* 67.5% in group I *vs* 77.5% in group II (P=NS) *Venous symptomatology* 29.7% in group I *vs* 25% in group II (P=NS)

	Hamel-Desnos C, Ouvry P, Benigni JP, Boitelle G, Schadeck M, Desnos P et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomized, double-blind trial with 2 year-follow-up. The 3/1 study. *Eur J Vasc Endovasc Surg*. 2007;34:723-729.	Multicentre study including 148 patients with incompetent GSV of diameter 4-8 mm UGFS with Turbofoam® Two concentrations of polidocanol; I injection Group I (N=74): polidocanol 1%; V= 4.6 ml Group II (N=74): polidocanol 3%; V= 4.4 ml **Results at 3 weeks of follow-up:** *Reflux abolition (RA):* 96% in group I *vs* 88% in group II *Length of GSV occlusion*: 38 cm in group I *vs* 34 cm in group II; P=NS **Results at 2 years of follow-up:** *Reflux abolition (RA):* 69% in group I *vs* 68% in group II **;** P=NS
	Blaise S, Bosson JL, Diamand JM. Ultrasound-Guided Sclerotherapy of the Great Saphenous Vein with 1% vs. 3% Polidocanol Foam: A Multicentre Double-Blind Randomised Trial with 3-Year Follow-Up. *Eur J Vasc Endovasc Surg*. 2010;39:779-86.	Multicentre study including 143 in C_2 to C_6 patients with incompetent GSV UGFS with Turbofoam® Two concentrations of polidocanol Group I (N=73): polidocanol 1%; V= 6.1 ml Group II (N=70): polidocanol 3%; V=6.3 ml *Complementary UGFS when persistent reflux present at 6 weeks 3 and 6 months:* 49% in group I *vs* 33% in group II; P=0.04 **Results at 6 months of follow-up:** *Reflux abolition (whether their SFJ was competent or not)***:** 69% in group I *vs* 85% in group II **Results at 3 years of follow-up:** 3.5% patients lost to follow-up *Reflux abolition:* 79% in group I *vs* 78% in group II **;** P=0.05 *Severity venous score, CIVIQ Score* No difference between groups at 3 years *Local side effects*: no difference between the 2 groups (9% vs. 6%; P=NS)

Abbreviations :
GSV= great saphenous vein; SFJ= saphenofemoral junction; SPJ= saphenopopliteal junction; UGFS = ultrasound guided foam sclerotherapy; V= Sclerosing agent injected volume